Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
#2PRI RANKED
Most Cited Paper
in Acute Myeloid Leukemia Research
18 Months Post-Publication
Class of 2026
“Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
Revumenib · Menin inhibitor · KMT2A rearrangement · Relapsed/refractory acute leukemia · Menin-KMT2A interaction · AUGMENT-101 · Complete remission (CR) · CR with partial hematologic recovery · NPM1 mutation · differentiation syndrome · QT interval prolongation · Measurable residual disease (MRD) · cytochrome P450 inhibitor · targeted therapy · phase II trial
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026. Accessed 2026-07-31. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459